Major Depressive Disorder (MDD) is a highly prevalent psychiatric disorder worldwide. It
causes individual suffering, loss of productivity, increased health care costs and high suicide …

Over 300 million people worldwide suffer from major depressive disorder (MDD).
Unfortunately, only 30–40% of patients with MDD achieve complete remission after …

Advanced sensing devices, highly sensitive, and reliable in detecting ultralow
concentrations of circulating biomarkers, are extremely desirable and hold great promise for …

We examined whether inflammation is uniformly associated with all depressive and anxiety
symptoms, and whether these associations are potentially causal. Data was from 147,478 …

The majority of COVID-19 survivors experience long-term neuropsychiatric symptoms such
as fatigue, sleeping difficulties, depression and anxiety. We propose that neuroimmune …

The long-term value of immunopsychiatry will be based on its ability to translate basic
science into effective clinical interventions. In this article, we discuss a key obstacle to …

Background About every fourth patient with major depressive disorder (MDD) shows
evidence of systemic inflammation. Previous studies have shown inflammation-depression …

Compelling evidence demonstrates that some individuals suffering from major depressive
disorder (MDD) exhibit increased levels of inflammation. Most studies focus on inflammation …

BackgroundDepression is associated with metabolic alterations including lipid
dysregulation, whereby associations may vary across individual symptoms. Evaluating these …

Personality is associated consistently with mortality hazards, but the physiological pathways
are not yet clear. Immune system dysregulation may be one such pathway due to its role in …